Samer Renno, MD
Hematology & Oncology · Omaha, NENPI 1588758312
Payments from drug & device makers
Across 149 payments — averaging $277.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Amgen$7K
- Seagen Inc.$6K
- AbbVie$5K
- Tesaro, Inc.$4K
- Johnson & Johnson$1K
- plus $3K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $14,538 |
| Amgen | 9 | $7,045 |
| Seagen Inc. | 12 | $6,259 |
| AbbVie | 19 | $4,749 |
| Tesaro, Inc. | 10 | $4,346 |
| Johnson & Johnson | 6 | $1,354 |
| Daiichi Sankyo Inc. | 7 | $1,061 |
| Mckesson Specialty Care Distribution, LLC | 1 | $670 |
| E.r. Squibb & Sons, L.L.C. | 16 | $232 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $138 |
| Iovance Biotherapeutics, Inc. | 1 | $123 |
| Merck | 6 | $99 |
| Eisai Inc. | 4 | $82 |
| Incyte Corporation | 1 | $82 |
| Novartis | 4 | $73 |
| Astellas Pharma US Inc | 3 | $71 |
| Genentech USA, Inc. | 3 | $66 |
| Acrotech Biopharma Inc. | 5 | $66 |
| Pharmaessentia USA Corporation | 3 | $62 |
| Pfizer | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Beone Medicines USA, Inc. | 1 | $34 |
| Octapharma USA, Inc. | 1 | $25 |
| Geron Corporation | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$41,380 in reported general payments places this provider in the 50th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$29.3M
- Ralph HaukeOmaha$12.1M
- Margaret BlockOmaha$8.3M
- Stefano TarantoloOmaha$3.7M
- Julie VoseOmaha$3.5M
- Robert BociekOmaha$3M
- Vijaya BhattOmaha$2.2M
- Mojtaba AkhtariOmaha$1.9M
- Mary WellsOmaha$1.6M
- Robert LangdonOmaha$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.